Belantamab Mafodotin in Relapsed/Refractory Myeloma Requires Multidisciplinary Effort
October 1st 2020Sanjay V. Patel, MD, FRCOphth, discusses the corneal-associated toxicities that can occur with belantamab mafodotin and the need for multidisciplinary management to optimally administer this agent.
From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma
September 25th 2020Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.